Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD?

Joia K. Capocchi, Claudia Figueroa-Romero, Sage J.B. Dunham, Gina Faraci, Jason A. Rothman, Katrine L. Whiteson, Dong-oh Seo, David M. Holtzman, Stefanie Grabrucker, Yvonne M. Nolan, Rima Kaddurah-Daouk, David A. Jett

Research output: Contribution to journalArticlepeer-review

Abstract

Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRDs) are broad-impact multifactorial neurodegenerative diseases. Their complexity presents unique challenges for developing effective therapies. This review highlights research presented at the 2024 Society for Neuroscience meeting which emphasized the gut microbiome’s role in AD pathogenesis by influencing brain function and neurodegeneration through the microbiota–gut–brain axis. This emerging evidence underscores the potential for targeting the gut microbiota to treat AD/ADRD.

Original languageEnglish
Article numbere1295242024
JournalJournal of Neuroscience
Volume44
Issue number41
DOIs
StatePublished - Oct 9 2024

Fingerprint

Dive into the research topics of 'Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD?'. Together they form a unique fingerprint.

Cite this